Jolanta Zaborniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jolanta Zaborniak has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Piotr Franciszek Jakub Lipiński
Department of Neuropeptides, Mossakowski Medical Research Institute Polish Academy of Sciences, 5 Pawińskiego Street, PL 02-106 Warsaw, Poland
2 shared publications - Piotr Garnuszek
Radioisotope Centre POLATOM, National Centre for Nuclear Research, 05-400 Otwock, Poland
2 shared publications - Antoni Jaroń
National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland
1 shared publication - Arkadiusz Sikora
National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland
1 shared publication - Dariusz Pawlak
Radioisotope Centre Polatom, National Centre for Nuclear Research, Otwock, Poland
1 shared publication - Justyna Pijarowska-Kruszyna
National Centre for Nuclear Research, Radioisotope Centre POLATOM, 05-400 Otwock, Poland
1 shared publication
Latest Publications
- Open Access
- 6 May 2021
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 17 (3) , 838-842
Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease
- 6 May 2021
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 17 (3) , 838-842
Open AccessVirtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease
- Open Access
- 8 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2731
PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties
A new PSMA ligand (PSMA-D4) containing the Glu-CO-Lys pharmacophore connected with a new linker system (L-Trp-4-Amc) and chelator DOTA was developed for radiolabeling with therapeutic radionuclides. Herein we describe the synthesis, radiolabeling, and preliminary biological evaluation of the novel PSMA-D4 ligand. Synthesized PSMA-D4 was characterized using TOF-ESI-MS, NMR, and HPLC methods. The novel compound was subject to molecular modeling with GCP-II to compare its binding mode to analogous reference compounds. The radiolabeling efficiency of PSMA-D4 with 177Lu, 90Y, 47Sc, and 225Ac was chromatographically tested. In vitro studies were carried out in PSMA-positive LNCaP tumor cells membranes. The ex vivo tissue distribution profile of the radioligands and Cerenkov luminescence imaging (CLI) was studied in LNCaP tumor-bearing mice. PSMA-D4 was synthesized in 24% yield and purity >97%. The radio complexes were obtained with high yields (>97%) and molar activity ranging from 0.11 to 17.2 GBq mcmol−1, depending on the radionuclide. In vitro assays confirmed high specific binding and affinity for all radiocomplexes. Biodistribution and imaging studies revealed high accumulation in LNCaP tumor xenografts and rapid clearance of radiocomplexes from blood and non-target tissues. These render PSMA-D4 a promising ligand for targeted therapy of prostate cancer (PCa) metastases.
- 8 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5) , 2731
Open AccessPSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties
A new PSMA ligand (PSMA-D4) containing the Glu-CO-Lys pharmacophore connected with a new linker system (L-Trp-4-Amc) and chelator DOTA was developed for radiolabeling with therapeutic radionuclides. Herein we describe the synthesis, radiolabeling, and preliminary biological evaluation of the novel PSMA-D4 ligand. Synthesized PSMA-D4 was characterized using TOF-ESI-MS, NMR, and HPLC methods. The novel compound was subject to molecular modeling with GCP-II to compare its binding mode to analogous reference compounds. The radiolabeling efficiency of PSMA-D4 with 177Lu, 90Y, 47Sc, and 225Ac was chromatographically tested. In vitro studies were carried out in PSMA-positive LNCaP tumor cells membranes. The ex vivo tissue distribution profile of the radioligands and Cerenkov luminescence imaging (CLI) was studied in LNCaP tumor-bearing mice. PSMA-D4 was synthesized in 24% yield and purity >97%. The radio complexes were obtained with high yields (>97%) and molar activity ranging from 0.11 to 17.2 GBq mcmol−1, depending on the radionuclide. In vitro assays confirmed high specific binding and affinity for all radiocomplexes. Biodistribution and imaging studies revealed high accumulation in LNCaP tumor xenografts and rapid clearance of radiocomplexes from blood and non-target tissues. These render PSMA-D4 a promising ligand for targeted therapy of prostate cancer (PCa) metastases.